Why Biotech and FinTech Are Primed for SPAC Deals
In this episode of The SPAC Podcast, Adeel Rouf dives into two of his highest-conviction sectors for upcoming SPAC activity: healthcare (specifically biotech) and FinTech. While AI and crypto dominate the headlines, Adeel makes the case for why some of the most overlooked, and deeply discounted, opportunities exist in these quieter corners of the market.
Biotech, he notes, has been heavily discounted since the market cooled in 2021–2023, leaving many high-quality companies undervalued and ready for smart capital. Meanwhile, the rapid evolution of digital assets and payment platforms makes FinTech a sector full of momentum. With SPACs already positioned in both verticals, Adeel outlines why these areas could lead the next wave of smart public listings.
Connect with the Guest:
Adeel Rouf – SPAC Sponsor & Investor
LinkedIn: https://www.linkedin.com/in/adeelrouf/
View all of their episodes here:
https://www.thespacpodcast.com/guests/adeel-rouf/
Connect with the Hosts & The SPAC Podcast:
Michael Blankenship LinkedIn:
https://www.linkedin.com/in/mikeblankenship/
Joshua Wilson LinkedIn:
https://www.linkedin.com/in/joshuabrucewilson/
YouTube Channel:
https://www.youtube.com/@Thespacpodcast
Contact The SPAC Podcast:
https://www.thespacpodcast.com/contact/
#SPACs #CapitalMarkets #SPACPodcast #Biotech #FinTech #SPACDeals #IPOAlternatives
The views, opinions, and statements expressed by the guest are solely their own and do not necessarily reflect the views of The SPAC Podcast, its hosts, or affiliated organizations. This content is for informational purposes only and should not be construed as investment, legal, tax, or accounting advice.
Disclaimer:
Michael J. Blankenship is a licensed attorney and is a partner at Winston & Strawn LLP. Joshua Wilson is a licensed Florida real estate broker and holds FINRA Series 79 and Series 63 licensure. The content of this podcast is intended for informational and educational purposes only and should not be interpreted as legal, financial, or compliance advice. The views and opinions expressed by the hosts and guests are their own and do not necessarily reflect the official policies or positions of any regulatory agency, law firm, employer, or organization.
Listeners are encouraged to consult their own legal counsel, compliance professionals, or financial advisors to ensure adherence to applicable laws and regulations, including those enforced by the SEC, FINRA, and other regulatory bodies. This podcast does not constitute a solicitation, offer, or recommendation of any financial products, securities transactions, or legal services.
Let’s Connect on LinkedIn:
👉 Michael J. Blankenship - https://www.linkedin.com/in/mikeblankenship/
👉 Joshua Bruce Wilson - https://www.linkedin.com/in/joshuabrucewilson/
To Contact Us or Collaborate:
Mike Blankenship:
What are your favorite hot industries at the moment? I know your SPACs are in healthcare, what sectors do you see as most attractive right now?
Adeel Rouf:
That might sound biased because my SPACs are in FinTech and healthcare, but I’ll start with what’s obvious: AI and crypto are hot sectors, and everyone’s watching them. But I also think they’re becoming overcrowded, which means we have to look carefully at quality, not just quantity.
In contrast, healthcare, especially biotech, has been like the orphan child in the public markets for the past few years. From 2021 to 2023, biotech traded at deep discounts and saw investors pull out. That’s exactly why I think it’s attractive now great companies are sitting at low valuations and could be excellent SPAC targets.
On the FinTech side, I’m especially excited about how digital asset infrastructure and payment platforms are evolving. These changes are shaping an entirely new financial landscape. That’s why I chose to launch SPACs in these two sectors, I see lasting value and real opportunity.
Adeel Rouf
CEO
Adeel Rouf is a seasoned financier and SPAC sponsor with a background spanning investment banking, capital markets, and corporate finance. He currently serves as the President and Chief Executive Officer of Voyager Acquisition Corp., a Nasdaq-listed special purpose acquisition company that recently announced a $1.3 billion merger with Veraxa Holdings, a Switzerland-based biotechnology firm.
Mr. Rouf is also the President and Chief Financial Officer of Titan Acquisition Corp., a fintech-focused SPAC that raised $277 million in its initial public offering. He has previously held officer and director roles in several other SPACs, demonstrating a consistent track record in sourcing, structuring, and executing complex transactions across sectors.
Earlier in his career, Mr. Rouf was part of J.P. Morgan’s Investment Banking Leveraged Finance team, where he focused on executing high-yield and structured debt financings. He also worked at Sumitomo Mitsui Banking Corporation, advising on structured credit and project finance deals.
He earned a BBA in Accounting from Baruch College and holds a Master of Science in Sustainability Management and Energy Finance from Columbia University.